Expiratory Flow Limitation in Thoracic Surgery (EFLinTOR)
NCT ID: NCT03814538
Last Updated: 2019-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2019-01-01
2020-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The presence of EFL measured by this method seems to correlate, in abdominal surgery, with the development of post-operative pulmonary complications. In the area of anesthesia in thoracic surgery, neither the incidence nor the relevance of the EFL are known, so a study is needed that evaluates both.
The aim of the study is to determine the incidence of expiratory flow limitation in patients undergoing thoracic surgery and ventilated in bi and monopolmonary mode.
The protective ventilation is a mechanical ventilation with a current volume (TV) of 6-8 mL / kg among to the ideal body weight (IBW), PEEP of 3-5 cmH2O and a FiO2 \<80%.
The aim of this study is to evaluate the incidence of EFL in patients undergoing thoracic surgery, planned by thoracoscopy and thoracotomy in election, and to correlate this parameter with the onset of postoperative pulmonary complications. The final aim will be to verify if it is possible to identify a better approach, through the personalization of mechanical ventilation during the surgery, to reduce mortality, morbidity and hospital stay after thoracic surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.
NCT06946498
Residual Block in Postoperative Anaesthetic Care Unit
NCT02930629
Comparison of Thoracoscopic Talc Pleurodesis by Thoracic Epidural or General Anesthesia
NCT01469728
Risk of Pneumothorax With and Without Chest Tube Clamping in Patients With Pleural Pathology
NCT05243316
Prospective Evaluation of Needle Exsufflation for Pneumothorax
NCT02528734
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The respiratory rate will be set to maintain PaCO2 at values close to eucapnia.
Controlled pressure ventilation (Pinsp ≤ 35 cmH2O) will be used only if the maximum airway pressures are reached and exceeded with controlled ventilation.
The inspiratory mixture will consist of O2: Air and possibly the halogenated anesthetic.
At the end of the operation, the patients will be transferred to Intensive Care Unit for post-operative monitoring. During the transfer will be supported with mechanical ventilation manually performed by the Anesthesiologist.
The extubation will be performed in TICCH, according to the practice of the center.
Patients will be asked to join the study by giving informed consent.
The data will be collected through a special data collection form (Case Report Form, CRF).
The following information will be collected:
In the section dedicated to the preoperative patient data will be inserted related to:
* age, weight, height, sex;
* general health conditions
* previous and concurrent diseases
* positive respiratory history for: previous pleuro-parenchymal diseases in the 30 days prior to surgery, previous interventions on the thorax, pleura or lung, presence of pleural effusion; asthma; Chronic obstructive pulmonary disease.
* history of cigarette smoking: active smoker (number of cigarettes), ex-smoker or non-smoker;
* Preoperative Therapy
* SpO2, PaO2, PaO2 / FiO2, PaCO2 (if available);
* cardiological anamnesis (echocardiography, ECG, etc.) other medical information relevant to the study
The following data will be collected on the intra-operative card:
* incidence of EFL and respiratory mechanics parameters, collected by the ventilator;
* type of surgical intervention;
* transfusion of blood derivatives;
* eventual administration of cardio / vasoactive drugs;
* duration of the surgery; other information related to the intra-operative relevant for the purpose of the study
The EFL will be registered at the following time-points:
* after the induction of anesthesia;
* after lateral positioning of the patient;
* start of One Lung Ventilation;
* 5 ' after cutting skin;
* 30 ' after cutting skin;
* 5 ' after closing skin;
* Bipulmonary ventilation;
* Positioning of the back of the patient.
The following data will be recorded in the postoperative card:
* Post-operative mechanical ventilation time
* postoperative respiratory complications;
* postoperative non-respiratory (cardiovascular, infectious, renal, surgical) complications;
* need for re-intubation in the postoperative period;
* need for ventilatory support (non-invasive ventilation, invasive ventilation) in the postoperative period;
* need for hospitalization in intensive care (expected, unexpected, cause of hospitalization, length of stay);
* duration of hospital stay; other postoperative information relevant for the purpose of the study.
Data will be analyzed using statistical software.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed informed consent
* elective thoracic surgery
* planned thoracic surgery with thoracotomy and thoracosthomy
Exclusion Criteria
* Pregnancy
* Patients undergoing emergency or emergency surgery
* Patients underwent cardiac and surgery
* patients underwent thoracic surgery with median sthernotomy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Parma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elena Giovanna Bignami
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michela Tosi, MD
Role: PRINCIPAL_INVESTIGATOR
University of Parma
Benedetta Siroli, MD
Role: PRINCIPAL_INVESTIGATOR
University of Parma
Samantha Gorgoglione, MD
Role: PRINCIPAL_INVESTIGATOR
University of Parma
Valentina Bellini, MD
Role: PRINCIPAL_INVESTIGATOR
University of Parma
Anna Cozzolino, MD
Role: PRINCIPAL_INVESTIGATOR
University of Parma
Cristina Montanino, MD
Role: PRINCIPAL_INVESTIGATOR
University of Parma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliera-Universitaria di Parma
Parma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
876/2018/OSS/AOUPR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.